



## Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 7, 2024

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34<sup>th</sup> Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: <https://investors.belitebio.com/presentations-events/events>. The replay will be archived for 90 days following the presentation date.

### About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinalrebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on [Twitter](#), [Instagram](#), [LinkedIn](#), [Facebook](#), or visit us at [www.belitebio.com](http://www.belitebio.com).

### Media and Investor Relations Contact:

Jennifer Wu  
[ir@belitebio.com](mailto:ir@belitebio.com)

Julie Fallon  
[belite@argotpartners.com](mailto:belite@argotpartners.com)



Source: Belite Bio, Inc